BridgeMD
New treatment option for Brain Tumor
Official title Development of MRF for Characterization of Brain Tumors After Radiotherapy
ClinicalTrials.gov ID: NCT06101069
What this study is testing
- What it's testing
- The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues.
- Time commitment: about 1 year
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60. Healthy volunteers may be eligible.
You may be able to join if
- for Healthy Participants:
- Ages 18 - 60
- No history of cerebrovascular disease
- No cognitive impairments
- Able to provide informed consent for Participants with Brain Tumors:
You likely can't join if
- Pregnant women OR lactating women
- Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
- Participants who cannot go into the MRI scanner due to metal implants and other medical conditions.
- The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator.
- Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other...
- Known history of severe claustrophobia.
See the full eligibility criteria
- for Healthy Participants:
- Ages 18 - 60
- No history of cerebrovascular disease
- No cognitive impairments
- Able to provide informed consent for Participants with Brain Tumors:
- Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR
- a. PET identified with developed recurrent tumor or radiation necrosis. OR
- b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon.
- ECOG performance status 0-2.
- Life expectancy \> 6 months.
- Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis. for Participants with...
- Radiology identified with developed primary gliomas tumor or brain metastases, OR
- a. PET identified with developed gliomas tumor or brain metastases, OR
- b. Highly suspicious case with developed gliomas tumor or brain metastases confirmed by tumor board
- Participants must not have received prior radiation or surgical treatment for brain metastases or primary glioma.
- Age: 18 years and over
- ECOG performance status 0-2
- Life expectancy \> 6 months.
- Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis. for Participants with...
- Radiology identified with resectable meningioma
- Participants have no prior radiation or surgical treatment for brain lesions
- Age: 18 years or older
- ECOG performance status 0-2
- Life expectancy \> 6 months.
- Participants with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis.
- Pregnant women OR lactating women
- Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips.
- Participants who cannot go into the MRI scanner due to metal implants and other medical conditions.
- The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator.
- Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material.
- Known history of severe claustrophobia.
- Participants unable to lay still in the scanner for 30 minutes at a time.
The study team makes the final eligibility decision.
Where it's taking place
- Cleveland, Ohio, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 1 year per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cleveland, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.